21 Results for "

L-M cell

" in MedChemExpress (MCE) Product Catalog:
Products (21)

21 Results for "L-M cell" in MCE Product Catalog:

8
8 Publications Verification
Cat. No.: HY-13442A
CAS No.: 441045-17-6
Purity:  99.91%
Synonyms: B1939 mesylate; E7389 mesylate; ER-086526 mesylate
Research Areas:  

Cancer

Eribulin mesylate is an inhibitor for microtubule. Eribulin mesylate inhibits the proliferation of cancer cell LM8 and Dunn, inhibits the cell migration of LM8, arrests the cell cycle at G2/M phase, and induces apoptosis in LM8. Eribulin mesylate exhibits antitumor efficacy in mouse model .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-110155
CAS No.: 1243259-19-9
Purity:  99.93%
Target:  

Neurotensin Receptor

Research Areas:  

Neurological Disease

LM11A-31 dihydrochloride, a non-peptide p75 NTR (neurotrophin receptor p75) modulator, is an orally active and potent proNGF (nerve growth factor) antagonist. LM11A-31 dihydrochloride is an amino acid derivative with high blood-brain barrier permeability and blocks p75-mediated cell death. LM11A-31 dihydrochloride reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-117088
CAS No.: 102562-74-3
Purity:  ≥95.0%
Target:  

Neurokinin Receptor

Research Areas:  

Neurological Disease

LM11A-31, a non-peptide p75 NTR (neurotrophin receptor p75) modulator, is an orally active and potent proNGF (nerve growth factor) antagonist. LM11A-31 is an amino acid derivative with high blood-brain barrier permeability and blocks p75-mediated cell death. LM11A-31 reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P99291
CAS No.: 892553-42-3
Synonyms: LM609; MEDI-522

Target:  

Integrin Apoptosis Akt

Research Areas:  

Cancer

Etaracizumab (LM 609) is an αvβ3 integrin IgG mAb. Etaracizumab is developed to target αvβ3+ cancer cells via NK cell-mediated cytotoxicity. Etaracizumab sterically hinders access of large ligands to the RGD-binding pocket, without obstructing it. Etaracizumab decreases p-Akt in vitro. Etaracizumab can decrease cancer proliferation and invasion. Etaracizumab induces tumor cell apoptosis, and inhibition ofαvβ3-mediated cell adhesion, endothelial cell migration and osteoclast-mediated bone resorption. Etaracizumab can be studied in anti-tumor research against cancers such as ovarian cancer, metastatic melanoma as well as advanced solid tumors. Recommend Isotype Control: Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-156112
CAS No.: 2055494-50-1
Purity:  99.78%
Target:  

Ser/Thr Protease

Research Areas:  

Cancer

LM2I is a derivative of Spinosyn A (SPA). LM2I is argininosuccinate synthase (ASS1) enzyme activator, and tumor inhibitor that directly interact with ASS1. LM2I has significant antiproliferative activity in seven colorectal cancer cell-lines and xenograft tumors of colorectal cancer. LM2I inhibits colorectal cancer cell growth via the EGFR pathway .
loading...
    loading...
Cat. No.: HY-P5362
NODAGA-LM3 is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC50 = 1.3 nM). NODAGA-LM3 does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. 68Ga-labeled NODAGA-LM3 can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .
loading...
    loading...
Cat. No.: HY-155309
CAS No.: 2996821-30-6
Purity:  99.82%
Target:  

YAP

Research Areas:  

Cancer

LM-41 is a Flufenamic acid-derived TEAD inhibitor hat strongly reduce the expression of CTGF, Cyr61, Axl and NF2. LM-41 inhibits migration of human MDA-MB-231 breast cancer cells .
loading...
    loading...
Cat. No.: HY-162650
CAS No.: 3054715-45-3
Target:  

ClpP

Research Areas:  

Cancer

SL44 is an agonist for human caseinolytic protease P (HsClpP), with an EC50 of 1.30 μM. SL44 inhibits the proliferation of LM3 with an IC50 of 3.1 μM. SL44 induces apoptosis in HCC cells, through the degradation of respiratory chain complex subunits. SL44 exhibits antitumor efficacy in mouse models without obvious toxicity (LD50=400 mg/kg). SL44 exhibits good pharmacokinetic characters in rat models .
loading...
    loading...
Cat. No.: HY-164102
CAS No.: 1272322-42-5
Target:  

TNF Receptor NF-κB

Research Areas:  

Inflammation/Immunology

TNF-α-IN-18 (Compound 61) is an inhibitor for TNF-α (IC50 of 1.8 μM), that inhibits TNF signaling pathway through block of NF-kB migration from cytoplasm to nucleus. TNF-α-IN-18 exhibits slight cytotoxicity to mouse fibroblast LM cell, with a CC50 >50 μM. TNF-α-IN-18 ameliorates the TNF- or Lipopolysaccharide (HY-D1056)-induced sepsis in mouse models. TNF-α-IN-18 protects mice from rheumatoid arthritis .
loading...
    loading...
Cat. No.: HY-171754
Research Areas:  

Cancer

LM-305 is an anti-G protein-coupled receptor class 5 member D (GPRC5D) antibody-drug conjugate (ADC). LM-305 consists of Anti-GPRC5D Antibody (HY-P991197) and VcMMAE (HY-15575). LM-305 exhibits potent cytotoxicity against multiple myeloma cells (NCI-H929 and MM.1R) with IC50 values ranging from 0.1 to 0.3 nM. LM-305 can be used in the study of GPRC5D-related relapsed and refractory multiple myeloma (RRMM) .
loading...
    loading...
Cat. No.: HY-13442C
CAS No.: 441045-17-6
Synonyms: B1939 mesylate (purity>99%, single impurity ≤ 0.15%); E7389 mesylate (purity>99%, single impurity ≤ 0.15%); ER-086526 mesylate (purity>99%, single impurity ≤ 0.15%)
Research Areas:  

Cancer

Eribulin (B1939; E7389; ER-086526) mesylate (purity>99%, single impurity ≤ 0.15%) is an inhibitor for microtubule. Eribulin mesylate (purity>99%, single impurity ≤ 0.15%) inhibits the proliferation of cancer cell LM8 and Dunn, inhibits the cell migration of LM8, arrests the cell cycle at G2/M phase, and induces apoptosis in LM8. Eribulin mesylate (purity>99%, single impurity ≤ 0.15%) exhibits antitumor efficacy in mouse model .
loading...
    loading...
Cat. No.: HY-164915
CAS No.: 1218932-97-8
Target:  

Bacterial

Research Areas:  

Metabolic Disease

5-InoAz is an inositol analogue containing an azide group, which is used as a metabolic probe for labeling the mycobacterial cell envelope. 5-InoAz integrates into cell envelope glycolipids [phosphatidylinositol mannoside (PIM), PIM-anchored lipomannan (LM), and lipoarabinomannan (LAM)] .
loading...
    loading...
Cat. No.: HY-P991738
Target:  

PD-1/PD-L1 VEGFR

Research Areas:  

Cancer

LM-299 is a bispecific antibody targeting PD-1 and VEGF with anti-tumor activity. The dual binding activity of LM-299 is achieved through the effective binding of its Fab-terminal anti-VEGF-A antibody to human VEGF-A, as well as the blocking effect of its Fc-terminal anti-PD-1 antibody on the PD-1/PD-L1 pathway. LM-299 binds to and modulates PD-1 and VEGF. LM-299 can be used in studies related to advanced malignant tumors, advanced solid tumors, and advanced non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-P99692
CAS No.: 156679-34-4
Synonyms: p55TNF-R:Ig; Ro 45-2081; TNFR55-IgG1

Target:  

TNF Receptor

Research Areas:  

Inflammation/Immunology

Lenercept (Ro 45-2081) is a recombinant fusion protein that consists of the soluble TNF-receptor (p55) linked to the Fc portion of human IgG1 .
loading...
    loading...
Cat. No.: HY-157975
Target:  

Glutaminase

Research Areas:  

Cancer

LM11 is an inhibitor of transglutaminase 2 (TG2) with an activity of killing glioblastoma cells by maintaining TG2 in a cytotoxic conformational state .
loading...
    loading...
Cat. No.: HY-P5362A
NODAGA-LM3 TFA is a ligand that can cross the blood-brain barrier and targets somatostatin receptor SSTR2 with high affinity (IC50 = 1.3 nM). NODAGA-LM3 TFA does not trigger the internalization of SSTR2 and can inhibit agonist-induced internalization processes. NODAGA-LM3 TFA shows low uptake in normal tissues such as the liver and spleen, but high uptake in the lungs and blood pool. 68Ga-labeled NODAGA-LM3 TFA can serve as a PET imaging agent for well-differentiated neuroendocrine tumors, and is applied in studies related to small cell lung cancer and well-differentiated neuroendocrine tumors .
loading...
    loading...
Cat. No.: HY-103043
CAS No.: 1400998-20-0
Target:  

Others

Research Areas:  

Cancer

Pz 285 is an anti-cancer agent. Pz 285 shows significant inhibitory effect on the viability of MDA-MB-231 breast cancer cells, with an IC50 of 15.0 μM. Pz 285 exhibits remarkable antitumor effects in the mouse tumor xenograft model constructed with highly lung-metastatic MDA-MB-231 LM24 Her2+ breast cancer cells. Pz 285 can be used for the study of breast cancer, especially metastatic breast cancer .
loading...
    loading...
Cat. No.: HY-179062
Target:  

Apoptosis

Research Areas:  

Cancer

Anticancer agent 280 (Compound 65) is an anti-cancer agent targeting triple-negative breast cancer (TNBC). Anticancer agent 280 exhibits IC50 values of Anticancer agent 280 for MDA-MB-231, MDA-MB-231/LM2-4, Jurkat, and MCF-7 of 7.1, 11.65, 6.99, and 21.51 μM respectively. Anticancer agent 280 can cause significant arrest of cells in the S phase and induce cell apoptosis. Anticancer agent 280 can be used for the study of TNBC .
loading...
    loading...
Cat. No.: HY-179070
Target:  

Apoptosis

Research Areas:  

Cancer

Anticancer agent 280 TFA (Compound 65) is an anti-cancer agent targeting triple-negative breast cancer (TNBC). Anticancer agent 280 TFA exhibits IC50 values of Anticancer agent 280 TFA for MDA-MB-231, MDA-MB-231/LM2-4, Jurkat, and MCF-7 of 7.1, 11.65, 6.99, and 21.51 μM respectively. Anticancer agent 280 TFA can cause significant arrest of cells in the S phase and induce cell apoptosis. Anticancer agent 280 TFA can be used for the study of TNBC .
loading...
    loading...
Cat. No.: HY-143402
CAS No.: 2770804-58-3
Target:  

Topoisomerase

Research Areas:  

Cancer

Topoisomerase I/II inhibitor 2 (compound 1a) is a potent Topoisomerase inhibitor (IC50= 9.82 μM on Huh7 cells and 6.83 μM on LM9 cells). Topoisomerase I/II inhibitor 2 has dual inhibition on DNA topoisomerase I/II, also can obviously reduce the growth of xenograft tumor in mice model. Topoisomerase I/II inhibitor 2 has the potential value in researching liver cancer .
loading...
    loading...